Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma- Renewal Grant Aim 2 (The SOS6C Trial)

NCT07212491 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07212491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07212491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma- Renewal Grant Aim 2 (The SOS6C Trial)
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Enrolling by invitation
Start date
November 17, 2025
Completion date
July 31, 2030
Enrollment
450 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

barrett esophagus, esophageal adenocarcinoma